medigraphic.com
ISSN 1029-3019 (Electronic)

2020, Number 04

<< Back Next >>

MediSan 2020; 24 (04)

Clinical, humoral, laparoscopic and histologic characterization of patients with antibodies against the hepatitis C virus

Caro FMT, Ortega SG, Martén MD, Suárez SMJ, González PMB

Language: Spanish
References: 20
Page: 641-652
PDF size: 1200.58 Kb.


ABSTRACT

Introduction: Hepatitis C is a viral infection that can be presented as a light disorder, during few weeks, or become into a chronic hepatic disease.
Objective: To characterize patients with antibodies against the hepatitis C virus according to clinical, humoral, laparoscopic and histological variables.
Methods: An observational, descriptive, serial cases study, of 150 patients with antibodies against the hepatitis C virus was carried out, they were assisted in the hepatology service of Dr. Juan Bruno Zayas Alfonso General Hospital in Santiago de Cuba from December, 2017 to the same month in 2019, to whom a hepatic biopsy by laparoscopy was carried out. The percentage was used as summary measure.
Results: There was a prevalence of the 61-70 age group and the female sex. The higher risk for the transmission of hepatitis C virus was by blood. In spite of being infected, the 45.3 % of patients had a clinical course in some moments of the disease with normal alanine aminotransferase values.
Conclusions: In the laparoscopic studies the normal liver and chronic hepatitis were more frequent, at the same time that these last ones prevailed with light and moderate lesions. The presence of tissue lesions was verified either in the symptomatic or asymptomatic patients.


REFERENCES

  1. Pears E. Hepatitis C virus infection: risk factors, diagnosis and management. Nurs Stand. 2010 [citado 21/02/2020]; 25(15-17):49-56. Disponible en: https://pubmed.ncbi.nlm.nih.gov/21309431/

  2. Arredondo Bruce A, Perez Trujillo E. Nuevos progresos en el enfrentamiento a la hepatitis C. Rev Med Electrón. 2018 [citado 21/02/2020];40(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1684-18242018000200014

  3. Millet Torres D, Curbelo Rodriguez L. Evolución general de receptores de trasplante renal con hepatitis C en el Hospital Provincial de Camagüey, Cuba. 2015. Nefrol (Madrid). 2015 [citado 21/02/2020];35(5). Disponible en. http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0211-69952015000500014

  4. Smit Donald B. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated Criteria and Genotype Assignment Web Resource. Hepatology. 2014 [citado 21/02/2020]; 59(1). Disponible en: https://pubmed.ncbi.nlm.nih.gov/24115039/

  5. World Health Organization. Global Hepatitis Report. Geneva: WHO; 2017 [citado 21/02/2020]. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf

  6. Factográfico de salud. Hepatitis. Estadísticas mundiales. 2019 [citado 21/02/2020]. Disponible en: http://www.sld.cu/anuncio/2019/08/24/factografico-de-salud-hepatitis-estadisticas-mundiales-0

  7. Cuba. Ministerio de Salud Pública. Plan Estratégico Nacional para la prevención y control de las ITS, VIH y las hepatitis 2019-2023. La Habana: MINSAP; 2019.

  8. Monsalve Castillo F, Gómez Gamboa L, Albillos A, Álvarez Mon M, Costa León L, Araujo Soto M, et al. Virus de la hepatitis C en poblaciones de riesgo a adquirir la infección. Rev Esp Enferm Dig. 2007 [citado 12/01/2011];6(99):3159. Disponible en: http://scielo.isciii.es/pdf/diges/v99n6/original1.pdf

  9. Hepatitis C: HCVAD [citado 31/07/2019]. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082007000600002

  10. Mitiko Tengan F, Yakub Ibrahim K, Peixoto Dantas B, Manchiero C, Cavalheiro Magri M, Marques Bernardo W. Seroprevalence of hepatitis C virus among people living with HIV/AIDS in Latin America and the Caribbean: A systematic review. BMC Infect Dis. 2016 [citado 08/05/2019];16:663. Disponible en: https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-016-1988-y

  11. Gane EJ, Hyland RH, Yang Y. Safety and efficacy of short-duration treatmen twith GS-9857 combined with sofosbuvir/GS-5816 in treatment-naive and DAA-experienced genotype1 patients with and without cirrhosis. Vienna: The International Liver Congress;2015 [citado 02/02/2016]. Disponible en: http://www.natap.org/2015/EASL/EASL_16.htm

  12. Lucas PE, Zavala MA. Detección de anticuerpos contra el virus de la hepatitis C en habitantes de la zona sur de Manabí, Ecuador. Kasmera. 2019 [21/02/2020]; 47(2):148-52. Disponible en: http://produccioncientificaluz.org/index.php/kasmera

  13. Cuba. Ministerio de Salud Pública. Dirección Nacional de Estadísticas. Anuario Estadístico de Salud 2016. La Habana: MINSAP; 2017 [citado 10/07/2019]. Disponible en:http://files.sld.cu/dne/files/2017/05/Anuario_Estad%C3%ADstico_de_Salud_e_2016_edici%C3%B3n_2017.pdf

  14. Organización Mundial de la Salud. Programa de la OMS sobre las hepatitis. Ginebra: OMS; 2019 [citado 15/07/2019]. Disponible en: https://www.who.int/hepatitis/es/

  15. Lozano Merida JA. Hepatitis C crónica. Vías de transmisión, diagnóstico, clínica y tratamiento. Offarm. 2004 [citado 15/07/2019];23(3). Disponible en: https://www.elsevier.es/es-revista-offarm-4-articulo-hepatitis-c-cronica-vias-transmision-13059412

  16. Traebert J, Porton Fratoni KR, Cabral Domingos da Rosa L, Traebert E, Ceola Schneinder IJ. The burden of hepatitis C infection in a Southern Brazilian State. Rev Soc Bras Med Trop. 2018 [citado 07/05/2019];51(5):670-3. Disponible en: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822018000500670&lng=en&tlng=en

  17. Vázquez Torres Y, Infante Velázquez I, Miranda Gómez O, Vázquez Torres YC, Vázquez Anovega H, Torres Sánchez C, et al. Detección de anticuerpos contra el virus de la hepatitis C en donantes de sangre voluntarios. Rev Cubana Med Gen Integr. 2017 [citado 07/05/2019];33(4). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21252017000400002

  18. Lozano Sepulveda S, Bryan Marrugo O, Merino Mascorro J, Rivas Estilla AM. Approachability to the new anti-HCV direct acting antiviral agents in the Latin American context. Future Virol. 2015 [citado 07/05/2019];11(1):39-46. Disponible en: https://www.researchgate.net/publication/287806836_Approachability_to_the_new_anti-HCV_direct_acting_antiviral_agents_in_the_Latin_American_context

  19. Moreno JV, Rodriguez del Rey P, Cardellá Rosales L. Hepatitis C III. Estudio laparóscópico, histológico y niveles serológicos de alaninotransferasa en 160 pacientes seropositivos al virus de la hepatitis C. Rev Cubana Biomed. 2005 [citado 07/05/2019];24(1):14-20. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-03002005000100002

  20. Ahmed A, Keeffe EB. Division of Gastroenterology and Hepatology. Gastroenterol. 2004 [citado 07/05/2019];126:1409-15. Disponible en: https://www.medschool.umaryland.edu/medicine/Divisions/Division-of-Gastroenterology-and-Hepatology/




2020     |     www.medigraphic.com